Lineagen, Inc. Selected to Present at the 2010 Genetic Risk Factors for Autism: Translating Discoveries into Diagnostics Symposium in Toronto

posted - SEP 02, 2010

SALT LAKE CITY--(BUSINESS WIRE)--Lineagen, Inc. (, a developer of innovative genomic tests and services for the screening, evaluation and diagnosis of complex disorders and diseases including autism spectrum disorders, announced today that Dr. Michael S. Paul, the Company’s President & Chief Executive Officer, was selected to present at the “Genetic Risk Factors for Autism: Translating Discoveries into Diagnostics” symposium, being held September 1-2, 2010 at the Old Mill Inn and Spa in Toronto, Ontario, Canada. The international symposium, sponsored in part by Autism Speaks, the Eunice Kennedy Shriver National Institute of Child Health and Human Development at the United States National Institute of Health (NIH), and the Canadian Institutes of Health Research (CIHR), serves as a forum to address the scientific, clinical, ethical, and related aspects of translating new Autism Spectrum Disorders (ASD) genetic discoveries into clinical screening and diagnostic tools.

“Lineagen is honored to have been invited to present at this prestigious symposium and to participate along with many of today’s ASD thought-leaders in sharing a better understanding of the scientific, clinical, and ethical implications of bringing new genetic discoveries into clinical practice for ASD. Lineagen’s selection as one of only five industry representatives to present their respective genetic research and commercialization initiatives indicates the compelling nature of Lineagen’s genetic discovery research efforts that have been conducted with geneticists and clinicians located at the University of Utah and at other world-leading pediatric clinical institutions. Lineagen is working to translate these efforts into clinically relevant diagnostic tools for the earlier assessment of a child’s risk of developing ASD based on their genetic profiles.” said Dr. Paul.

The fastest-growing developmental disability in the U.S., autism affects up to one in every 110 children, creating a huge personal – and national – economic burden. Studies suggest that early intensive behavioral intervention (EIBI) can lead to significant levels of improvement. Despite this, the vast majority of children remain undiagnosed until age five or six due to “bottlenecks” along the physician referral pathway, as well as limited early diagnostic technologies.

About Lineagen, Inc.

Lineagen ( is a provider of diagnostic and healthcare services focused on complex diseases for which individuals’ genetic profiles contribute strongly to their susceptibility. Lineagen is committed to improving outcomes for those affected by autism and other complex diseases, for which effective early diagnosis and intervention can have a significant positive impact. The Company’s comprehensive genetic testing and support/counseling service are initially designed to enable early evaluation of children at risk for disorders of childhood development, including autism spectrum disorders (ASDs). Founded in 2002, Lineagen’s commercial strategy represents the culmination of significant proprietary research into genetic causes and diagnostic pathways of key complex diseases, including autism, MS and COPD. One of the company’s core research competitive advantages is its access through the University of Utah to the Utah Poulation Database, an unmatched biomarker discovery research platform that has been used to help the University identify more disease-related genes than any other institution in the world.

For more information see

« back to article list